Scope Fluidics Spolka AkcyjnaWAR:SCP -1.32%49 PB Ratio is 2.55 as of Jul. 03, 2026, which is 61% below its 10-year median of 6.47. GuruFocus rates WAR:SCP with a GF Score™ of 49/100 and a GF Value™ of zł129.86 (Fairly Valued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Scope Fluidics Spolka Akcyjna ranks worse than 60.82% on this metric.
Scope Fluidics Spolka Akcyjna stock PB Ratio (=2.52) is close to 3-year low of 2.48.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's PB Ratio or its related term are showing as below:
WAR:SCP'
s PB Ratio Range Over the Past 10 Years
Min: 1.38 Med: 6.47 Max: 31.55
Current: 2.55
During the past 10 years, Scope Fluidics Spolka Akcyjna's highest PB Ratio was 31.55. The lowest was 1.38. And the median was 6.47.
WAR:SCP's PB Ratio is ranked worse than 60.82% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.045
vs WAR:SCP: 2.55
During the past 12 months, Scope Fluidics Spolka Akcyjna's average Book Value Per Share Growth Rate was -5.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -25.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 60.90% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Scope Fluidics Spolka Akcyjna was 177.60% per year. The lowest was -25.10% per year. And the median was 38.80% per year.
Back to Basics: PB Ratio
Scope Fluidics Spolka Akcyjna (WAR:SCP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Scope Fluidics Spolka Akcyjna PB Ratio Related Terms
Scope Fluidics Spolka Akcyjna PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Scope Fluidics Spolka Akcyjna's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scope Fluidics Spolka Akcyjna PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Scope Fluidics Spolka Akcyjna's PB Ratio distribution charts can be found below:
* The bar in red indicates where Scope Fluidics Spolka Akcyjna's PB Ratio falls into.
Scope Fluidics Spolka Akcyjna PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a PB Ratio of 2.55 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. This is 61% below median its historical median of 6.47. Over the past decade, Scope Fluidics Spolka Akcyjna's PB Ratio has ranged from 1.38 to 31.55. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #118 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 60.8%.
Is Scope Fluidics Spolka Akcyjna's PB Ratio too high?
Scope Fluidics Spolka Akcyjna's current PB Ratio of 2.55 is 61% below median its 10-year median of 6.47. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 31.55. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Scope Fluidics Spolka Akcyjna's value of 2.55 is 24.7% above this industry median. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #118 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #118 out of 194 companies for PB Ratio. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. The industry median PB Ratio is 2.05. Scope Fluidics Spolka Akcyjna's value of 2.55 is 24.7% above this benchmark. Historically, Scope Fluidics Spolka Akcyjna's own PB Ratio has ranged from 1.38 to 31.55 over the past decade. While the company's 10-year median is 6.47 vs. the industry median of 2.05, Scope Fluidics Spolka Akcyjna has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scope Fluidics Spolka Akcyjna's current PB Ratio of 2.55 is 24.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current PB Ratio is 2.55, which is 61% below median its own 10-year median of 6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł129.86, compared to a current price of zł120.00 — trading 7.6% below its estimated fair value. The current PB Ratio is 2.55, which is 61% below median its 10-year median of 6.47 and 24.7% above the Medical Diagnostics & Research industry median of 2.05. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current PB Ratio is 2.55 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued.
The current stock price of zł120.00 is trading 7.6% below its estimated GF Value™ of zł129.86.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
PB Ratio: 2.55 (61% below median its 10-year median of 6.47)
GF Value™: zł129.86 vs. price of zł120.00 (7.6% below fair value)
Industry Position: 24.7% above the Medical Diagnostics & Research median (#118 of 194)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna Business Description
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
49GF Score
Get the complete analysis for WAR:SCP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
